Research Article
BibTex RIS Cite

Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats

Year 2023, Volume: 27 Issue: 5, 1799 - 1807, 28.06.2025

Edward Davis Dion Notario Tena Djuartina Dyonesia Ary Harjanti Ignatius Ivan Linawati Hananta

Abstract

Current antihypertensive drugs are still limited to be used as a monotherapy and their effectiveness in preventing end-organ damage is insufficient, therefore complementary therapy is needed to reduce end-organ damage and make hypertension treatment more effective. In this study, we are investigating the potential of bovine lactoferrin (BLf) as an antihypertensive and renal protective agent. 30 rats were randomly divided into 6 groups: BLf 100mg/kg, BLf 300 mg/kg, BLf 500 mg/kg, Dexamethasone, Amlodipine 1 mg/kg, and Control. Dexamethasone, Amlodipine 1mg/kg, and all BLf groups were given subcutaneous dexamethasone injections from day 1 to 14. Starting from day 8 to 14 Amlodipine 1 mg/kg and BLf groups received oral BLf or amlodipine according to mentioned doses. The results of this study demonstrated that BLf at all doses was effective in lowering systolic blood pressure, increasing serum nitric oxide (NO) level, and improving kidney function but ineffective in lowering diastolic blood pressure. BLf has the potential to be utilized as a complementary antihypertensive therapy and renal protective agent in hypertension.

Keywords

bovine lactoferrin nitric oxide systolic blood pressure diastolic blood pressure renal protective dexamethasone

References

  • [1] Chockalingam A, Campbell NR, Fodor JG. Worldwide epidemic of hypertension. Can J Cardiol. 2006;22(7):553-555. https://doi.org/10.1016/s0828-282x(06)70275-6
  • [2] Ren-Ren BA, Xiao-Ming WU, Jin-Yi XU. Current natural products with antihypertensive activity. Chin J Nat Med. 2015;13(10):721-729. https://doi.org/10.1016/s1875-5364(15)30072-8
  • [3] Fekete ÁA, Givens DI, Lovegrove JA. Can milk proteins be a useful tool in the management of cardiometabolic health? An updated review of human intervention trials. Proc Nutr Soc. 2016;75(3):328-341. https://doi.org/10.1017/s0029665116000264
  • [4] Hidayat K, Du HZ, Yang J, Chen GC, Zhang Z, Li ZN, Qin LQ. Effects of milk proteins on blood pressure: a meta-analysis of randomized control trials. Hypertens Res. 2017;40(3):264-270. https://doi.org/10.1038/hr.2016.135
  • [5] Safaeian L, Zabolian H. Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat. ISRN Pharmacol. 2014;2014:943523. https://doi.org/10.1155/2014/943523
  • [6] Giansanti F, Panella G, Leboffe L, Antonini G. Lactoferrin from milk: Nutraceutical and pharmacological properties. Pharmaceuticals (Basel). 2016;9(4):61. https://doi.org/10.3390/ph9040061
  • [7] Prasetya A, Soetedjo R, Tandecxi G, Rosadi BL, Davis E, Stella MM, Ivan I, Hananta L. Potential effects of lactoferrin as antiviral and neoadjuvant therapy in pediatric patients with viral gastroenteritis. J Pediatr Neonat Individual Med. 2021;10(2):e100214. https://doi.org/10.7363/100214
  • [8] Hayashida K, Takeuchi T, Ozaki T, Shimizu H, Ando K, Miyamoto A, Harada E. Bovine lactoferrin has a nitric oxide-dependent hypotensive effect in rats. Am J Physiol Regul Integr Comp Physiol. 2004;286(2):R359-365. https://doi.org/10.1152/ajpregu.00214.2003
  • [9] Ong SL, Whitworth JA. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin. 2011;40(2):393-407. https://doi.org/10.1016/j.ecl.2011.01.010
  • [10] Wallerath T, Witte K, Schäfer SC, Schwarz PM, Prellwitz W, Wohlfart P, Kleinert H, Lehr HA, Lemmer B, Förstermann U. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A. 1999;96(23):13357-13362. https://doi.org/10.1073/pnas.96.23.13357
  • [11] Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, Matsumoto T. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res. 2003;92(1):81-87. https://doi.org/10.1161/01.res.0000050588.35034.3c
  • [12] Ono H, Ono Y, Takanohashi A, Matsuoka H, Frohlich ED. Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension. 2001;38(6):1300-306. https://doi.org/10.1161/hy1201.096118
  • [13] Lahera VI, Salom MG, Miranda-Guardiola FA, Moncada SA, Romero JC. Effects of NG-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol. 1991;261(6):1033-1037. https://doi.org/10.1152/ajprenal.1991.261.6.f1033
  • [14] Zhao Y, Vanhoutte PM, Leung SW. Vascular nitric oxide: Beyond eNOS. J Pharmacol Sci. 2015;129(2):83-94. https://doi.org/10.1016/j.jphs.2015.09.002
  • [15] Giles TD, Sander GE, Nossaman BD, Kadowitz PJ. Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial‐derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens. 2012;14(4):198-205. https://doi.org/10.1111/j.1751-7176.2012.00606.x
  • [16] Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li PL, Ritter JK. Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci. 2018;19(9):2605. https://doi.org/10.3390/ijms19092605
  • [17] Smits JF, Struyker-Boudier HA. The mechanisms of antihypertensive action of beta-adrenergic receptor blocking drugs. Clin Exp Hypertens A. 1982;4(1-2):71-86. https://doi.org/10.3109/10641968209061577
  • [18] Ghatage T, Goyal SG, Dhar A, Bhat A. Novel therapeutics for the treatment of hypertension and its associated complications: Peptide-and nonpeptide-based strategies. Hypertens Res. 2021;44(7):740-755. https://doi.org/10.1038/s41440-021-00643-z
  • [19] Schmieder RE. End organ damage in hypertension. Dtsch Arztebl Int. 2010;107(49):866-873. https://doi.org/10.3238/arztebl.2010.0866
  • [20] Baylis C. Nitric oxide synthase derangements and hypertension in kidney disease. Curr Opin Nephrol Hypertens. 2012;21(1):1-6. https://doi.org/10.1097/mnh.0b013e32834d54ca
  • [21] Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens. 2013;22(1):1-9. https://doi.org/10.1097/mnh.0b013e32835b36c1
  • [22] Griffin K, Polichnowski A, Licea-Vargas H, Picken M, Long J, Williamson G, Bidani A. Large BP-dependent and-independent differences in susceptibility to nephropathy after nitric oxide inhibition in Sprague-Dawley rats from two major suppliers. Am J Physiol Renal Physiol. 2012;302(1):173-182. https://doi.org/10.1152/ajprenal.00070.2011
  • [23] Gowda S, Desai PB, Kulkarni SS, Hull VV, Math AA, Vernekar SN. Markers of renal function tests. N Am J Med Sci. 2010;2(4):170-173.
  • [24] Yamauchi K, Toida T, Nishimura S, Nagano E, Kusuoka O, Teraguchi S, Hayasawa H, Shimamura S, Tomita M. 13-Week oral repeated administration toxicity study of bovine lactoferrin in rats. Food Chem Toxicol. 2000;38(6):503-512. https://doi.org/10.1016/s0278-6915(00)00036-3
  • [25] Charan J, Kantharia N. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4(4):303-306. https://doi.org/10.4103/0976-500X.119726
  • [26] Arifin WN, Zahiruddin WM. Sample size calculation in animal studies using resource equation approach. Malays J Med Sci. 2017;24(5):101-105. https://doi.org/10.21315/mjms2017.24.5.11
  • [27] Fares H, DiNicolantonio JJ, O'Keefe JH, Lavie CJ. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016;3(2):e000473. https://doi.org/10.1136/openhrt-2016-000473
  • [28] Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27. https://doi.org/10.4103/0976-0105.177703
  • [29] Wigati D, Anwar K, Sudarsono, Nugroho AE. Hypotensive activity of ethanolic extracts of Morinda citrifolia L. leaves and fruit in dexamethasone-induced hypertensive rat. J Evid Based Complementary Altern Med. 2017;22(1):107-113. https://doi.org/10.1177/2156587216653660
  • [30] Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. Free Radical Biol Med. 2007;43(5):645-657. https://doi.org/10.1016/j.freeradbiomed.2007.04.026
  • [31] Ralston PB, Strein TG. A study of deproteinization methods for subsequent serum analysis with capillary electrophoresis. Microchem J. 1997;55:270-283. https://doi.org/10.1006/mchj.1996.1421
  • [32] Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide. 2001;5(1):62-71. https://doi.org/10.1006/niox.2000.0319
There are 32 citations in total.

Details

Primary Language English
Subjects Pharmacology and Pharmaceutical Sciences (Other)
Journal Section Articles
Authors

Edward Davis 0000-0002-0625-4533

Dion Notario 0000-0001-7376-3517

Tena Djuartina 0000-0002-4281-5852

Dyonesia Ary Harjanti 0000-0001-6221-1151

Ignatius Ivan 0000-0001-6177-3793

Linawati Hananta 0000-0002-2068-4345

Publication Date June 28, 2025
Published in Issue Year 2023 Volume: 27 Issue: 5

Cite

APA Davis, E., Notario, D., Djuartina, T., Harjanti, D. A., et al. (2025). Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats. Journal of Research in Pharmacy, 27(5), 1799-1807.
AMA Davis E, Notario D, Djuartina T, Harjanti DA, Ivan I, Hananta L. Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats. J. Res. Pharm. July 2025;27(5):1799-1807.
Chicago Davis, Edward, Dion Notario, Tena Djuartina, Dyonesia Ary Harjanti, Ignatius Ivan, and Linawati Hananta. “Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats”. Journal of Research in Pharmacy 27, no. 5 (July 2025): 1799-1807.
EndNote Davis E, Notario D, Djuartina T, Harjanti DA, Ivan I, Hananta L (July 1, 2025) Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats. Journal of Research in Pharmacy 27 5 1799–1807.
IEEE E. Davis, D. Notario, T. Djuartina, D. A. Harjanti, I. Ivan, and L. Hananta, “Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats”, J. Res. Pharm., vol. 27, no. 5, pp. 1799–1807, 2025.
ISNAD Davis, Edward et al. “Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats”. Journal of Research in Pharmacy 27/5 (July 2025), 1799-1807.
JAMA Davis E, Notario D, Djuartina T, Harjanti DA, Ivan I, Hananta L. Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats. J. Res. Pharm. 2025;27:1799–1807.
MLA Davis, Edward et al. “Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats”. Journal of Research in Pharmacy, vol. 27, no. 5, 2025, pp. 1799-07.
Vancouver Davis E, Notario D, Djuartina T, Harjanti DA, Ivan I, Hananta L. Antihypertensive and Renal Protective Effect of Bovine Lactoferrin in Dexamethasone-Induced Hypertension Rats. J. Res. Pharm. 2025;27(5):1799-807.